InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,712.69
(
-0.28%
)
US TECH 100
19,513.20
(
0.37%
)
Dow Jones
41,794.60
(
-0.61%
)
Brent Oil
75.45
(
0.44%
)
Bitcoin
68,806.68
(
1.46%
)
Post# of 64738
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Houndish

Send PM Follow Ignore
Followers 1
Posts 581
Boards Moderated 0
Alias Born 04/03/2006

Houndish

Re: None

Thursday, 07/20/2006 8:21:22 PM

Thursday, July 20, 2006 8:21:22 PM

Post# of 64738
SIMPLIVIR Update

Anyone?

Toxicology testing is ongoing, and Pre-IND discussions with FDA experts in the Division of Cellular and Gene Therapies within CBER have helped to clarify the additional pre-clinical requirements to facilitate filing of an Investigational New Drug (IND) application.
And these requirements are????

When additional supporting studies using SIMPLIVIR based on synDNA™ are complete, we will file an IND to allow for clinical evaluation of the product.
Which supporting studies do they speak of? The last study I found relating to SIMPLIVIR report was released on Mar 2nd 2005... over a year ago.

I think as owners of the company we're due for an update.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up